Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp Capital Intensity

The Capital Intensity Ratio of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 13, 2026 is 363.74 %. In the previous year, Capital Intensity Ratio was 331.08 % — a change of 9.87% (higher).

Capital Intensity

363.74 %

YoY

9.87%

Last updated:

Capital Intensity Ratio of Vcanbio Cell & Gene Engineering Corp is 2025 363.74 % . Capital Intensity Ratio of Vcanbio Cell & Gene Engineering Corp was 2024 331.08 % . It decreases by 9.87% higher compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
336.49 CNY
Jan 1, 2019
352.51 CNY
Jan 1, 2020
369.97 CNY
Jan 1, 2021
327.84 CNY
Jan 1, 2022
339.87 CNY
Jan 1, 2023
340.40 CNY
Jan 1, 2024
331.08 CNY
Jan 1, 2025
363.74 CNY
The Vcanbio Cell & Gene Engineering Corp Capital Intensity history
YEARCapital IntensityYoY
363.74 %+9.87%
331.08 %-2.74%
340.40 %+0.15%
339.87 %+3.67%
327.84 %-11.39%
369.97 %+4.95%
352.51 %+4.76%
336.49 %+48.15%
227.13 %-36.64%
358.47 %-9.75%
397.20 %-21.63%
506.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp., Ltd. generates revenue through the development and sale of life sciences technology products. The company produces cytokines culture solutions, cosmetics, and detection reagents for domestic markets. Its business segments include cell culture, gene detection and storage, and the production of specialized biological products. The firm's domestic customers primarily purchase these products for research and commercial applications in the life sciences sector. Vcanbio focuses on cell culture and gene detection services, which are integral to its product offerings. The company's cytokines culture solutions are sold to domestic clients in the biotechnology and pharmaceutical industries. Detection reagents are also marketed to domestic laboratories and healthcare providers for diagnostic purposes. The firm leverages its 2,332 full-time employees to support research, development, and production activities. The company's product portfolio includes cosmetics alongside scientific reagents, targeting both consumer and professional markets. Domestic markets remain the primary focus for all sales, with no mention of international operations. Vcanbio's revenue streams are derived from the sale of its core products, which are developed and manufactured in-house. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Capital Intensity Ratio of Vcanbio Cell & Gene Engineering Corp is 363.74 % in 2025.

Capital Intensity Ratio of Vcanbio Cell & Gene Engineering Corp changed from 331.08 % to 363.74 %, representing a 9.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Vcanbio Cell & Gene Engineering Corp with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Vcanbio Cell & Gene Engineering Corp

All Key Metrics — Vcanbio Cell & Gene Engineering Corp